Advertisement

Der Urologe

, Volume 58, Issue 1, pp 25–29 | Cite as

Instillationstherapien beim Urothelkarzinom des oberen Harntraktes

  • P. Bosshard
  • G. N. ThalmannEmail author
  • B. Roth
Leitthema
  • 72 Downloads

Zusammenfassung

Traditionell galt das Urothelkarzinom des oberen Harntrakts (OHT) als klare Indikation zur radikalen Nephroureterektomie mit Blasenmanschettenresektion. Bei gut selektionierten Patienten und abhängig vom Tumorstadium zeigt sich jedoch, dass eine nierenerhaltende Therapie onkologisch zu ähnlich guten Ergebnissen wie eine Nephroureterektomie führen kann. Eine wichtige Rolle in der nierenerhaltenden Therapie nimmt nebst der lokalen Tumortherapie mittels ablativer ureteroskopischer Verfahren (u. a. Laserverfahren) das Verhindern von Rezidiven lokal wie auch in der Blase ein. Instillationstherapien des OHT mit Bacillus Calmette-Guérin und/oder Mitomycin C haben diesbezüglich Erfolge erzielt. Die Datenlage ist jedoch aufgrund der Seltenheit der Erkrankung sowie der meist retrospektiven Studien eingeschränkt. Im Folgenden geben wir einen Überblick über die Indikationen, die technische Durchführung und die Resultate der Instillationstherapie des OHT.

Schlüsselwörter

Bacillus Calmette-Guérin Mitomycin C Nephroureterektomie Vesikoureteraler Reflux Carcinoma in situ 

Instillation therapies for urothelial carcinoma of the upper urinary tract

Abstract

Traditionally, urothelial carcinoma of the upper urinary tract was a clear indication for radical nephroureterectomy with bladder cuff excision. It has been shown that in well-selected patients and depending on tumor stage, a kidney-sparing approach can be pursued with good oncological outcome and equivalent to the radical approach. The prevention of local and bladder recurrences is an important factor. Instillation therapies with bacillus Calmette-Guérin and/or mitomycin C have been successfully used to this end. Due to the low incidence of upper tract urothelial cancer and due to the usually retrospective nature of existing literature, however, data is limited. In this article, we provide a review of the indication, technical execution and results of instillation therapies of the upper urinary tract.

Keywords

Bacillus Calmette-Guérin Mitomycin C Nephroureterectomy Vesico-ureteral reflux Carcinoma in situ 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

P. Bosshard, G.N. Thalmann und B. Roth geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Aboumarzouk OM, Somani B, Ahmad S et al (2013) Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma. Urol Ann 5:184–189CrossRefGoogle Scholar
  2. 2.
    Chade DC, Shariat SF, Godoy G et al (2010) Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol 184:74–80CrossRefGoogle Scholar
  3. 3.
    Chen GL, Bagley DH (2000) Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. J Urol 164:1173–1176CrossRefGoogle Scholar
  4. 4.
    Cutress ML, Stewart GD, Wells-Cole S et al (2012) Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int 110:1608–1617CrossRefGoogle Scholar
  5. 5.
    Cutress ML, Stewart GD, Zakikhani P et al (2012) Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int 110:614–628CrossRefGoogle Scholar
  6. 6.
    Daneshmand S, Quek ML, Huffman JL (2003) Endoscopic management of upper urinary tract transitional cell carcinoma: long-term experience. Cancer 98:55–60CrossRefGoogle Scholar
  7. 7.
    European Association of Urology Guidelines (2018) EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS) 2018. In: 2018 edition. European Association of Urology Guidelines Office, ArnhemGoogle Scholar
  8. 8.
    Fang D, Li XS, Xiong GY et al (2013) Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis. Urol Int 91:291–296CrossRefGoogle Scholar
  9. 9.
    Gadzinski AJ, Roberts WW, Faerber GJ et al (2010) Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol 183:2148–2153CrossRefGoogle Scholar
  10. 10.
    Giannarini G, Kessler TM, Birkhauser FD et al (2011) Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol 60:955–960CrossRefGoogle Scholar
  11. 11.
    Grasso M, Fraiman M, Levine M (1999) Ureteropyeloscopic diagnosis and treatment of upper urinary tract urothelial malignancies. Urology 54:240–246CrossRefGoogle Scholar
  12. 12.
    Herr HW (1985) Durable response of a carcinoma in situ of the renal pelvis to topical bacillus Calmette-Guerin. J Urol 134:531–532CrossRefGoogle Scholar
  13. 13.
    Horiguchi H, Yoneyama T, Hatakeyama S et al (2018) Impact of bacillus Calmette-Guerin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy. Med Oncol 35:41CrossRefGoogle Scholar
  14. 14.
    Huang WC, Levey AS, Serio AM et al (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7:735–740CrossRefGoogle Scholar
  15. 15.
    Irie A, Iwamura M, Kadowaki K et al (2002) Intravesical instillation of bacille Calmette-Guerin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology 59:53–57CrossRefGoogle Scholar
  16. 16.
    Jarrett TW, Sweetser PM, Weiss GH et al (1995) Percutaneous management of transitional cell carcinoma of the renal collecting system: 9‑year experience. J Urol 154:1629–1635CrossRefGoogle Scholar
  17. 17.
    Krabbe LM, Lotan Y, Bagrodia A et al (2014) Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract—is there evidence for discordant biology? J Urol 191:926–931CrossRefGoogle Scholar
  18. 18.
    Martinez-Pineiro JA, Garcia Matres MJ, Martinez-Pineiro L (1996) Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J Urol 156:377–385CrossRefGoogle Scholar
  19. 19.
    Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116:180–183CrossRefGoogle Scholar
  20. 20.
    Nunez-Nateras R, Castle EP, Protheroe CA et al (2014) Predicting response to bacillus Calmette-Guerin (BCG) in patients with carcinoma in situ of the bladder. Urol Oncol 32:45e23–45e30CrossRefGoogle Scholar
  21. 21.
    Pettenati C, Ingersoll MA (2018) Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol 15(10):615CrossRefGoogle Scholar
  22. 22.
    Pollard ME, Levinson AW, Shapiro EY et al (2013) Comparison of 3 upper tract anticarcinogenic agent delivery techniques in an ex vivo porcine model. Urology 82:1451.e1–1451.e6CrossRefGoogle Scholar
  23. 23.
    Raymundo EM, Lipkin ME, Banez LB et al (2011) Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma. J Endourol 25:377–384CrossRefGoogle Scholar
  24. 24.
    Rouprêt M, Babjuk M, Burger M et al (2018) EAU guidelines on upper urinary tract urothelial carcinoma 2018. In: European Association of Urology (Hrsg) 2018 edition. European Association of Urology Guidelines Office, ArnhemGoogle Scholar
  25. 25.
    Roupret M, Hupertan V, Traxer O et al (2006) Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology 67:1181–1187CrossRefGoogle Scholar
  26. 26.
    Sfakianos JP, Cha EK, Iyer G et al (2015) Genomic characterization of upper tract urothelial carcinoma. Eur Urol 68:970–977CrossRefGoogle Scholar
  27. 27.
    Sorokin I, Welliver RC Jr., Elkadi O et al (2013) Tumor seeding of percutaneous nephrostomy tract from urothelial carcinoma of the kidney. Case Rep Urol 2013:819470PubMedPubMedCentralGoogle Scholar
  28. 28.
    Thalmann GN, Markwalder R, Walter B et al (2002) Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol 168:1381–1385CrossRefGoogle Scholar
  29. 29.
    Thompson RH, Krambeck AE, Lohse CM et al (2008) Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. Urology 71:713–717CrossRefGoogle Scholar
  30. 30.
    Xylinas E, Rink M, Margulis V et al (2013) Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int 112:453–461CrossRefGoogle Scholar
  31. 31.
    Yakoubi R, Colin P, Seisen T et al (2014) Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: a meta-analysis and a systematic review of current evidence from comparative studies. Eur J Surg Oncol 40:1629–1634CrossRefGoogle Scholar
  32. 32.
    Zhang Z, Furge KA, Yang XJ et al (2010) Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. BMC Med Genomics 3:58CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Urologische Universitätsklinik, InselspitalUniversitätsspital BernBernSchweiz

Personalised recommendations